Pulmonx to Report Third Quarter 2020 Financial Results on November 10, 2020
Pulmonx Corporation (NASDAQ: LUNG) will release its third-quarter financial results on November 10, 2020, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pulmonx Corporation (NASDAQ: LUNG) will release its third-quarter financial results on November 10, 2020, after market close. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The company specializes in minimally invasive treatments for lung disease, particularly for severe emphysema/COPD patients. The Zephyr® Endobronchial Valve, part of its treatment solutions, has received FDA pre-market approval and is available in over 25 countries with more than 80,000 valves used on over 20,000 patients.
Positive
- Zephyr Valve has received FDA pre-market approval as a breakthrough device.
- The Zephyr Valve is commercially available in over 25 countries.
- More than 80,000 valves have been used to treat over 20,000 patients.
Negative
- None.
Details
News Market Reaction – LUNG
The recorded move for LUNG in the trading session of this news was -1.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2020 after the close of trading on Tuesday, November 10, 2020. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (833) 614-1518 for domestic callers or (270) 823-1072 for international callers, followed by Conference ID: 7802229. A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx® Corporation (NASDAQ: LUNG) is a global leader in minimally invasive treatments for lung disease. The Pulmonx solution, which is comprised of the Zephyr® Endobronchial Valve (Zephyr Valve), the Chartis® Pulmonary Assessment System (Chartis System) and the StratX® Lung Analysis Platform, is designed to treat severe emphysema/COPD patients who, despite medical management, are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is now commercially available in more than 25 countries, with over 80,000 valves used to treat more than 20,000 patients. For more information, visit www.Pulmonx.com.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.